{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:22:21Z","timestamp":1792801341375,"version":"4.5.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Basic Science Research Program"},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2019R1A2C2085462"],"award-info":[{"award-number":["NRF-2019R1A2C2085462"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Dipeptidyl peptidase 4 (DPP4) inhibitors are widely used hypoglycaemic agents and improve glucose metabolism by enhancing the bioavailability of active glucagon-like peptide-1. In this study, we hypothesized that treatment with DPP4 inhibitors may have beneficial effects on nigrostriatal dopamine and longitudinal motor performance in diabetic patients with Parkinson\u2019s disease. We classified 697 drug naive patients with de novo Parkinson\u2019s disease who had undergone dopamine transporter imaging into three groups according to a prior diagnosis of diabetes and use of DPP4 inhibitors: diabetic patients with Parkinson\u2019s disease being treated with (n\u2009=\u200954) or without DPP4 inhibitors (n\u2009=\u200985), and non-diabetic patients with Parkinson\u2019s disease (n\u2009=\u2009558). Diabetic patients with Parkinson\u2019s disease being treated with DPP4 inhibitors had a higher baseline dopamine transporter availability in the anterior (2.56\u2009\u00b1\u20090.74 versus 2.10\u2009\u00b1\u20090.50; P\u2009=\u20090.016), posterior (1.83\u2009\u00b1\u20090.69 versus 1.40\u2009\u00b1\u20090.50; P\u2009&amp;lt;\u20090.001), and ventral putamina (1.72\u2009\u00b1\u20090.58 versus 1.35\u2009\u00b1\u20090.37; P\u2009=\u20090.001) than that in diabetic patients with Parkinson\u2019s disease without DPP4 inhibitors. Additionally, diabetic patients with Parkinson\u2019s disease being treated with DPP4 inhibitors had higher dopamine transporter availability in the posterior putamen than that in non-diabetic patients with Parkinson\u2019s disease (1.83\u2009\u00b1\u20090.69 versus 1.43\u2009\u00b1\u20090.59; P\u2009&amp;lt;\u20090.001). After adjusting for age, sex, disease duration, and vascular risk factors, linear regression models showed that a prior treatment of DPP4 inhibitors remained independently and significantly associated with dopamine transporter availability in the anterior (\u03b2 = \u22120.186, P\u2009=\u20090.012; \u03b2 = \u22120.207, P\u2009=\u20090.003), posterior (\u03b2 = \u22120.336, P\u2009&amp;lt;\u20090.001; \u03b2 = \u22120.286, P\u2009&amp;lt;\u20090.001), and ventral putamina (\u03b2 = \u22120.204, P\u2009=\u20090.005; \u03b2 = \u22120.250, P\u2009&amp;lt;\u20090.001). A linear mixed model revealed that the diabetic group with Parkinson\u2019s disease being treated with DPP4 inhibitors had a slower longitudinal increase in levodopa-equivalent dose than the other groups (P\u2009=\u20090.003). Survival analyses showed that the rate of levodopa-induced dyskinesia was significantly lower in the diabetic group with a prior treatment with DPP4 inhibitors than the diabetic group without DPP4 inhibitors (hazard ratio = 0.194, P\u2009=\u20090.037). These findings suggest that DPP4 inhibitors may confer beneficial effects on the baseline nigrostriatal dopamine degeneration and long-term motor outcomes in diabetic patients with Parkinson\u2019s disease and may extend its role into non-diabetic patients with Parkinson\u2019s disease.<\/jats:p>","DOI":"10.1093\/brain\/awab015","type":"journal-article","created":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T20:19:22Z","timestamp":1611519562000},"page":"1127-1137","source":"Crossref","is-referenced-by-count":63,"title":["Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson\u2019s disease"],"prefix":"10.1093","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4439-4390","authenticated-orcid":false,"given":"Seong Ho","family":"Jeong","sequence":"first","affiliation":[{"name":"Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jong","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea"},{"name":"Department of Neurology, Yongin Severance Hospital, Yonsei University Health System, Yongin, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-3352","authenticated-orcid":false,"given":"Han Soo","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namki","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Ho","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7215-375X","authenticated-orcid":false,"given":"Kyoungwon","family":"Baik","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young H","family":"Sohn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil Hyu","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea"},{"name":"Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,25]]},"reference":[{"key":"2021070719511960800_awab015-B1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.molmed.2015.04.005","article-title":"Type 2 diabetes as a protein misfolding disease","volume":"21","author":"Mukherjee","year":"2015","journal-title":"Trends Mol Med."},{"key":"2021070719511960800_awab015-B2","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.neurobiolaging.2005.04.017","article-title":"Common mechanisms of amyloid oligomer pathogenesis in degenerative disease","volume":"27","author":"Glabe","year":"2006","journal-title":"Neurobiol Aging."},{"key":"2021070719511960800_awab015-B3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.molmed.2013.01.002","article-title":"Shared dysregulated pathways lead to Parkinson's disease and diabetes","volume":"19","author":"Santiago","year":"2013","journal-title":"Trends Mol Med."},{"key":"2021070719511960800_awab015-B4","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2337\/dc10-1922","article-title":"Diabetes and risk of Parkinson's disease","volume":"34","author":"Xu","year":"2011","journal-title":"Diabetes Care."},{"key":"2021070719511960800_awab015-B5","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1212\/WNL.0b013e3182553cc9","article-title":"Clinical features of Parkinson disease when onset of diabetes came first: A case-control study","volume":"78","author":"Cereda","year":"2012","journal-title":"Neurology."},{"key":"2021070719511960800_awab015-B6","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.parkreldis.2013.01.016","article-title":"Diabetes is associated with postural instability and gait difficulty in Parkinson disease","volume":"19","author":"Kotagal","year":"2013","journal-title":"Parkinsonism Relat Disord."},{"key":"2021070719511960800_awab015-B7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.acra.2015.07.014","article-title":"Diabetes, gray matter loss, and cognition in the setting of Parkinson disease","volume":"23","author":"Petrou","year":"2016","journal-title":"Acad Radiol."},{"key":"2021070719511960800_awab015-B8","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","article-title":"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes","volume":"303","author":"Phung","year":"2010","journal-title":"JAMA."},{"key":"2021070719511960800_awab015-B9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/dom.12432","article-title":"Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline","volume":"17","author":"Gault","year":"2015","journal-title":"Diabetes Obes Metab."},{"key":"2021070719511960800_awab015-B10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40478-018-0517-1","article-title":"Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin","volume":"6","author":"Lietzau","year":"2018","journal-title":"Acta Neuropathol Commun."},{"key":"2021070719511960800_awab015-B11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1742-2094-9-44","article-title":"Dipeptidyl peptidase IV, aminopeptidase N and DPIV\/APN-like proteases in cerebral ischemia","volume":"9","author":"Rohnert","year":"2012","journal-title":"J Neuroinflammation."},{"key":"2021070719511960800_awab015-B12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.exger.2009.12.004","article-title":"Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice","volume":"45","author":"D'Amico","year":"2010","journal-title":"Exp Gerontol."},{"key":"2021070719511960800_awab015-B13","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00493","article-title":"Dipeptidyl peptidase-4 inhibitors for the potential treatment of brain disorders: A mini-review with special focus on linagliptin and stroke","volume":"10","author":"Darsalia","year":"2019","journal-title":". Front Neurol."},{"key":"2021070719511960800_awab015-B14","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1007\/s12035-016-0125-7","article-title":"Linagliptin, a dipeptidyl peptidase-4 inhibitor, mitigates cognitive deficits and pathology in the 3xTg-AD mouse model of Alzheimer's disease","volume":"54","author":"Kosaraju","year":"2017","journal-title":"Mol Neurobiol."},{"key":"2021070719511960800_awab015-B15","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jnc.13087","article-title":"Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: Role of RAGE-NFkappaB and Nrf2-antioxidant signaling pathways","volume":"133","author":"Abdelsalam","year":"2015","journal-title":"J Neurochem."},{"key":"2021070719511960800_awab015-B16","doi-asserted-by":"crossref","first-page":"8959","DOI":"10.1038\/s41598-018-27395-0","article-title":"Repositioning of Omarigliptin as a once-weekly intranasal anti-Parkinsonian agent","volume":"8","author":"Ayoub","year":"2018","journal-title":"Sci Rep."},{"key":"2021070719511960800_awab015-B17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10787-017-0331-6","article-title":"Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease","volume":"25","author":"Badawi","year":"2017","journal-title":"Inflammopharmacol."},{"key":"2021070719511960800_awab015-B18","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/mds.26734","article-title":"Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors\u2014A nationwide case-control study","volume":"31","author":"Svenningsson","year":"2016","journal-title":"Mov Disord."},{"key":"2021070719511960800_awab015-B19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.archger.2007.08.012","article-title":"An adaptation of the Korean mini-mental state examination (K-MMSE) in elderly Koreans: Demographic influence and population-based norms (the AGE study)","volume":"47","author":"Han","year":"2008","journal-title":"Arch Gerontol Geriatr."},{"key":"2021070719511960800_awab015-B20","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mds.25383","article-title":"How to identify tremor dominant and postural instability\/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale","volume":"28","author":"Stebbins","year":"2013","journal-title":"Mov Disord."},{"key":"2021070719511960800_awab015-B21","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.2337\/dc14-S081","article-title":"Diagnosis and classification of diabetes mellitus","volume":"37","year":"2014","journal-title":"Diabetes Care."},{"key":"2021070719511960800_awab015-B22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2967\/jnumed.111.095224","article-title":"Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy","volume":"53","author":"Oh","year":"2012","journal-title":"J Nucl Med."},{"key":"2021070719511960800_awab015-B23","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1097\/WNR.0000000000000247","article-title":"Cerebellum-specific 18F-FDG PET analysis for the detection of subregional glucose metabolism changes in spinocerebellar ataxia","volume":"25","author":"Oh","year":"2014","journal-title":"Neuroreport."},{"key":"2021070719511960800_awab015-B24","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","article-title":"Consensus nomenclature for in vivo imaging of reversibly binding radioligands","volume":"27","author":"Innis","year":"2007","journal-title":"J Cereb Blood Flow Metab."},{"key":"2021070719511960800_awab015-B25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0022-510X(93)90041-V","article-title":"A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging","volume":"114","author":"Scheltens","year":"1993","journal-title":"J Neurol Sci."},{"key":"2021070719511960800_awab015-B26","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov Disord."},{"key":"2021070719511960800_awab015-B27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/RLU.0000000000002251","article-title":"The pattern of striatal dopamine depletion as a prognostic marker in de novo Parkinson disease","volume":"43","author":"Chung","year":"2018","journal-title":"Clin Nucl Med."},{"key":"2021070719511960800_awab015-B28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.parkreldis.2018.05.008","article-title":"Putaminal dopamine depletion in de novo Parkinson's disease predicts future development of wearing-off","volume":"53","author":"Chung","year":"2018","journal-title":"Parkinsonism Relat Disord."},{"key":"2021070719511960800_awab015-B29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/bdd.662","article-title":"Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats","volume":"30","author":"Fuchs","year":"2009","journal-title":"Biopharm Drug Dispos."},{"key":"2021070719511960800_awab015-B30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1385\/JMN:18:1-2:07","article-title":"Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier","volume":"18","author":"Kastin","year":"2002","journal-title":"J Mol Neurosci."},{"key":"2021070719511960800_awab015-B31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci."},{"key":"2021070719511960800_awab015-B32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1677\/JOE-09-0132","article-title":"Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease","volume":"202","author":"Kim","year":"2009","journal-title":"J Endocrinol."},{"key":"2021070719511960800_awab015-B33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience."},{"key":"2021070719511960800_awab015-B34","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: A randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet."},{"key":"2021070719511960800_awab015-B35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0165-0173(94)00007-C","article-title":"Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop","volume":"20","author":"Parent","year":"1995","journal-title":"Brain Res Brain Res Rev."},{"key":"2021070719511960800_awab015-B36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0306-4522(94)90182-1","article-title":"The organization of midbrain projections to the striatum in the primate: Sensorimotor-related striatum versus ventral striatum","volume":"59","author":"Lynd-Balta","year":"1994","journal-title":"Neuroscience."},{"key":"2021070719511960800_awab015-B37","first-page":"227","article-title":"Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease","volume":"46","author":"Weintraub","year":"2005","journal-title":"J Nucl Med."},{"key":"2021070719511960800_awab015-B38","doi-asserted-by":"crossref","first-page":"e1248","DOI":"10.4088\/JCP.15m10154","article-title":"Increased dipeptidyl peptidase-4 activity is associated with high prevalence of depression in middle-aged and older adults: A cross-sectional study","volume":"77","author":"Zheng","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"2021070719511960800_awab015-B39","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.parkreldis.2018.08.023","article-title":"Detrimental effect of type 2 diabetes mellitus in a large case series of Parkinson's disease","volume":"64","author":"Chung","year":"2019","journal-title":"Parkinsonism Relat Disord."},{"key":"2021070719511960800_awab015-B40","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2017.00551","article-title":"Parkinson's disease severity at 3\u2009years can be predicted from non-motor symptoms at baseline","volume":"8","author":"Ayala","year":"2017","journal-title":"Front Neurol."},{"key":"2021070719511960800_awab015-B41","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s12640-019-9998-3","article-title":"Sitagliptin and liraglutide modulate L-dopa effect and attenuate dyskinetic movements in rotenone-lesioned rats","volume":"35","author":"Badawi","year":"2019","journal-title":"Neurotox Res."},{"key":"2021070719511960800_awab015-B42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat Rev Neurosci."},{"key":"2021070719511960800_awab015-B43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.2006.04124.x","article-title":"Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia","volume":"99","author":"Cenci","year":"2006","journal-title":"J Neurochem."},{"key":"2021070719511960800_awab015-B44","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejphar.2009.12.023","article-title":"Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease","volume":"630","author":"McClean","year":"2010","journal-title":"Eur J Pharmacol."},{"key":"2021070719511960800_awab015-B45","doi-asserted-by":"crossref","first-page":"e1654","DOI":"10.1212\/WNL.0000000000005475","article-title":"Diabetes mellitus and Parkinson disease","volume":"90","author":"Pagano","year":"2018","journal-title":"Neurology."},{"key":"2021070719511960800_awab015-B46","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3390\/ijerph16152720","article-title":"The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: When to select, what to expect","volume":"16","author":"Makrilakis","year":"2019","journal-title":"Int J Environ Res Public Health."},{"key":"2021070719511960800_awab015-B47","doi-asserted-by":"crossref","first-page":"S671","DOI":"10.1002\/mds.22600","article-title":"Clinical measures of progression in Parkinson's disease","volume":"24","author":"Poewe","year":"2009","journal-title":"Mov Disord."}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awab015\/37345254\/awab015.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/144\/4\/1127\/37903192\/awab015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/144\/4\/1127\/37903192\/awab015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T21:29:53Z","timestamp":1625693393000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/144\/4\/1127\/6250906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,25]]},"published-print":{"date-parts":[[2021,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awab015","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2021,4,1]]}}}